BR9914393A - Método para a obtenção de beta-ngf ativo - Google Patents

Método para a obtenção de beta-ngf ativo

Info

Publication number
BR9914393A
BR9914393A BR9914393-3A BR9914393A BR9914393A BR 9914393 A BR9914393 A BR 9914393A BR 9914393 A BR9914393 A BR 9914393A BR 9914393 A BR9914393 A BR 9914393A
Authority
BR
Brazil
Prior art keywords
ngf
beta
active beta
proforma
obtaining active
Prior art date
Application number
BR9914393-3A
Other languages
English (en)
Other versions
BR9914393B1 (pt
BRPI9914393B1 (pt
Inventor
Rainer Rudolph
Anke Rattenholl
Elisabeth Schwarz
Adelbert Grossmann
Original Assignee
Scil Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh filed Critical Scil Proteins Gmbh
Publication of BR9914393A publication Critical patent/BR9914393A/pt
Publication of BR9914393B1 publication Critical patent/BR9914393B1/pt
Publication of BRPI9914393B1 publication Critical patent/BRPI9914393B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>MéTODO PARA A OBTENçãO DE BETA-NGF ATIVO''<D>. A invenção refere-se a um método para a produção de beta NGF biologicamente ativo oriundo da pró-forma proNGT. Depois da expressão da pró-forma do beta-NGF em uma célula de hospedeiro procariótica, a proteína recombinante é isolada na forma de agregados insolúveis (corpos de inclusão). Depois da sua solubilização em um agente de desnaturação forte e a sua conversão subseq³ente na conformação natural, que é determinada pelas pontes de dissulfeto presentes no beta-NGF natural, beta-NGF biologicamente ativo é obtido por liberação por ruptura subseq³ente da pró-seq³ência.
BRPI9914393-3A 1998-10-09 1999-10-11 Método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante BRPI9914393B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98119077.0 1998-10-09
EP98119077A EP0994188B1 (de) 1998-10-09 1998-10-09 Verfahren zur Gewinnung von aktivem Beta-NGF
PCT/EP1999/007613 WO2000022119A1 (de) 1998-10-09 1999-10-11 VERFAHREN ZUR GEWINNUNG VON AKTIVEM β-NGF

Publications (3)

Publication Number Publication Date
BR9914393A true BR9914393A (pt) 2001-06-26
BR9914393B1 BR9914393B1 (pt) 2021-06-22
BRPI9914393B1 BRPI9914393B1 (pt) 2021-06-22

Family

ID=

Also Published As

Publication number Publication date
ES2213861T3 (es) 2004-09-01
KR100593831B1 (ko) 2006-06-28
US8501439B2 (en) 2013-08-06
CA2346257C (en) 2005-03-01
US8318671B1 (en) 2012-11-27
NL300894I2 (nl) 2018-02-01
JP2010280717A (ja) 2010-12-16
JP4634611B2 (ja) 2011-02-16
BR9914393B1 (pt) 2021-06-22
JP5275306B2 (ja) 2013-08-28
EP0994188A1 (de) 2000-04-19
CA2346257A1 (en) 2000-04-20
ZA200102780B (en) 2002-07-04
US20100203589A1 (en) 2010-08-12
KR20010083900A (ko) 2001-09-03
FR17C0007I1 (fr) 2017-11-17
JP2002527062A (ja) 2002-08-27
AU1034800A (en) 2000-05-01
FR17C0007I2 (fr) 2018-11-09
WO2000022119A1 (de) 2000-04-20
DE59810555D1 (de) 2004-02-12
ATE257514T1 (de) 2004-01-15
EP0994188B1 (de) 2004-01-07
AU765810B2 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
Jortikka et al. Immobilisation causes longlasting matrix changes both in the immobilised and contralateral joint cartilage
Poole et al. Analysis of the morphology and function of primary cilia in connective tissues: a cellular cybernetic probe?
Rowe et al. Regulation of collagen synthesis in fetal rat calvaria by 1, 25-dihydroxyvitamin D3.
FR17C0007I2 (fr) Procédé d&#39;obtention du NGF-bêta biologiquement actif
BRPI0411552A (pt) anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
NO973745L (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
BR9813811A (pt) &#34;composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo&#34;
BR9813968A (pt) Moléculas de ácido nucléico que codificam proteìnas tendo atividade frutosil transferase e processos para produzir inulina de cadeia longa
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
WO2005042048A3 (en) Bioactive hydrogel compositions for regenerating connective tissue
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9815551A (pt) Vacina de envoltório dimérica recombinante contra infecção flaviviral
Glimcher et al. Changes in tissue morphology and collagen composition during the repair of cortical bone in the adult chicken.
BR0003800A (pt) Processo para o fracionamento de dispersões de polìmeros
Conn et al. Matrix protein profiles in calf bone development
De Buren Causes and treatment of non-union in fractures of the radius and ulna
BR9712391A (pt) Processo para a preparação de um confeito de gelo
Abrass The nature of chronic progressive nephropathy in aging rats
Roughley et al. Comparison of proteoglycans extracted from high and low weight-bearing human articular cartilage, with particular reference to sialic acid content.
Carvalho et al. Isolation and characterization of a new lectin from the venom of the snake Bothrops jararacussu
PT1095141E (pt) Metodo para a producao de um peptido com um pi acima de 8 ou abaixo de 5
BR9907269A (pt) Agente de transferência de ácidos nucleicos, composição, utilização de um agente de transferência, e, processos de transferência de ácidos nucleicos nas células, de preparação de uma composição e de tratamento de doenças.
Thalmann et al. Otosclerosis: a local manifestation of a generalized connective tissue disorder?

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: WACKER CHEMIE AG (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2691 DE 02-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.